IMW 2021 | Dasatinib plus nivolumab in patients with previously treated CML
Joaquin Martinez-Lopez
• 10 Sep 2021
Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, discusses a Phase I trial investigating the safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia (CML). Dr Martinez-Lopez reports that this combination has a favourable safety profile; however, the preliminary results showed low response rates. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Joaquin Martinez-Lopez, MD, PhD, has received grant support from BMS; and has performed consultancy work for BMS, Janssen, Novartis, GSK, Incyte, Roche and Astellas.
